Lindbrook Capital LLC Acquires 565 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Lindbrook Capital LLC raised its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 19.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,519 shares of the company’s stock after purchasing an additional 565 shares during the period. Lindbrook Capital LLC’s holdings in Dr. Reddy’s Laboratories were worth $245,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Robeco Institutional Asset Management B.V. boosted its stake in shares of Dr. Reddy’s Laboratories by 15.0% in the third quarter. Robeco Institutional Asset Management B.V. now owns 1,673,126 shares of the company’s stock valued at $111,882,000 after buying an additional 218,605 shares during the period. Aikya Investment Management Ltd bought a new position in shares of Dr. Reddy’s Laboratories in the fourth quarter worth $75,850,000. Vanguard Group Inc. raised its stake in Dr. Reddy’s Laboratories by 2.0% in the third quarter. Vanguard Group Inc. now owns 1,048,152 shares of the company’s stock valued at $70,090,000 after purchasing an additional 20,341 shares in the last quarter. Acadian Asset Management LLC lifted its position in Dr. Reddy’s Laboratories by 26.9% during the third quarter. Acadian Asset Management LLC now owns 270,260 shares of the company’s stock worth $18,066,000 after purchasing an additional 57,293 shares during the period. Finally, Grantham Mayo Van Otterloo & Co. LLC increased its holdings in Dr. Reddy’s Laboratories by 47.5% in the 3rd quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 250,788 shares of the company’s stock valued at $16,770,000 after buying an additional 80,784 shares during the period. Institutional investors and hedge funds own 14.02% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on RDY. Jefferies Financial Group cut shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a research note on Thursday, January 11th. StockNews.com raised Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, April 5th. Finally, Barclays upped their price objective on Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Dr. Reddy’s Laboratories currently has an average rating of “Hold” and an average price target of $80.00.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $72.10 on Tuesday. The company’s 50 day moving average price is $74.37 and its two-hundred day moving average price is $70.31. The firm has a market capitalization of $12.03 billion, a P/E ratio of 19.02, a P/E/G ratio of 1.77 and a beta of 0.58. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.55 and a quick ratio of 1.90. Dr. Reddy’s Laboratories Limited has a fifty-two week low of $53.12 and a fifty-two week high of $77.72.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. The business had revenue of $867.00 million for the quarter, compared to analyst estimates of $827.81 million. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. On average, equities analysts forecast that Dr. Reddy’s Laboratories Limited will post 3.96 earnings per share for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.